Sugi Predict

Sugi Predict / Compounds / SCHEMBL1972884

SCHEMBL1972884

SCHEMBL1972884

O=C(O)Cc1ccc(=O)[nH]c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.48
▸ CAMK2A Q9UQM7 1/20 0.48
▸ AKR1B1 P15121 1/20 0.46
▸ LMNA P02545 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ ABCC4 O15439 1/20 0.45
▸ PTGS1 P23219 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ HPGD P15428 3/20 0.44
▸ HSD17B10 Q99714 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ POLB P06746 2/20 0.44
▸ RGS12 O14924 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ APEX1 P27695 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19466166 0.85 ABCC4 (0.58) CA2CAMK2AAKR1B1LMNAGAA
SCHEMBL21102002 0.82 MET (0.43) LMNAGAAALDH1A1MEN1KMT2A
SCHEMBL11702840 0.82 CA2 (0.50) CA2ALDH1A1KDM4EMEN1KMT2A
SCHEMBL30564438 0.80 FFAR1 (0.52) CA2LMNAL3MBTL1FFAR1P4HTM
SCHEMBL5739617 0.77 CYP4F2 (0.51) LMNAGAATSHRALDH1A1HPGD
SCHEMBL25357290 0.76 SLC7A5 (0.56) LMNATSHRPTGS1ALDH1A1HSD17B10
SCHEMBL10683581 0.76 SLC7A5 (0.56) LMNATSHRPTGS1ALDH1A1HSD17B10
SCHEMBL1160586 0.76 — —
SCHEMBL22501787 0.75 L3MBTL1 (0.45) LMNAGAATSHRKDM4EMEN1
SCHEMBL20751417 0.74 PKM (0.47) LMNAGAATSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119823097-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2025-04-15 — — CN disclosed
US-12268687-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-08 — — US disclosed
CN-115551845-B PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2025-02-28 — — CN disclosed
US-20250034124-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2025-01-30 — — US disclosed
US-20250034125-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2025-01-30 — — US disclosed
US-12098146-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-09-24 — — US disclosed
US-20230227426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-07-20 — — US disclosed
US-20230227426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-07-20 — — US disclosed
US-20230227426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-07-20 — — US disclosed
US-20230116101-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. 2023-04-13 — — US disclosed
US-20210139471-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2021-05-13 — — US disclosed
US-20210139471-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2021-05-13 — — US disclosed
US-10844017-B2 Biaryl compound, preparation method and use thereof FUDAN UNIVERSITY (CN) 2020-11-24 — — US disclosed
WO-2020154571-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-07-30 — — WO disclosed
WO-2020154571-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-07-30 — — WO disclosed
US-8609699-B2 Oxotetrahydrofuran-2-yl-benzimidazole derivative MSD K.K. (JP) 2013-12-17 — — US disclosed
EP-2328892-B1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2013-01-16 — — EP disclosed
US-20110144162-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-16 — — US disclosed
EP-2328892-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE MSD K.K. (JP) 2011-06-08 — — EP disclosed
WO-2010024110-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144162-A1 OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE GCK, GCKR, KHK CA2 605/4885CAMK2A 2200/4885AKR1B1 87/4885
US-20250034124-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 CA2 741/4885CAMK2A 703/4885AKR1B1 1461/4885
US-12268687-B2 Compounds and uses thereof NLN, BDNF, NQO1 CA2 741/4885CAMK2A 703/4885AKR1B1 1461/4885
US-10844017-B2 Biaryl compound, preparation method and use thereof RORC, RORB, RORA CA2 4192/4885CAMK2A 2118/4885AKR1B1 365/4885
US-20230227426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 CA2 719/4885CAMK2A 2163/4885AKR1B1 890/4885
US-20230116101-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 CA2 741/4885CAMK2A 703/4885AKR1B1 1461/4885
US-20250034125-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 CA2 741/4885CAMK2A 703/4885AKR1B1 1461/4885
US-20210139471-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 CA2 741/4885CAMK2A 703/4885AKR1B1 1461/4885
US-12098146-B2 Compounds and uses thereof NLN, BDNF, NQO1 CA2 741/4885CAMK2A 703/4885AKR1B1 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.